US009408381B2

(12) **United States Patent**
Ghatnekar et al.

(10) **Patent No.: US 9,408,381 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES FOR USE IN TRANSPLANT**

(71) Applicant: **MUSC Foundation for Research Development**, Charleston, SC (US)

(72) Inventors: **Gautam Ghatnekar**, Charleston, SC (US); **Robert Gourdie**, Charleston, SC (US); **Jane Jourdan**, Charleston, SC (US)

(73) Assignee: **MUSC FOUNDATION FOR RESEARCH DEVELOPMENT**, Charleston, SC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/932,630**

(22) Filed: **Nov. 4, 2015**

(65) **Prior Publication Data**

US 2016/0120171 A1 May 5, 2016

Related U.S. Application Data

(60) Continuation-in-part of application No. 13/935,848, filed on Jul. 5, 2013, now abandoned, which is a continuation-in-part of application No. 13/842,506, filed on Mar. 15, 2013, now Pat. No. 8,916,515, which is a continuation of application No. 13/715,626, filed on Dec. 14, 2012, now Pat. No. 8,809,257, which is a continuation of application No. 12/871,461, filed on Aug. 30, 2010, now Pat. No. 8,357,668, which is a division of application No. 11/721,529, filed as application No. PCT/US2005/046442 on Dec. 20, 2005, now Pat. No. 7,786,074, said application No. 13/935,848 is a continuation of application No. 12/665,596, filed as application No. PCT/US2008/067944 on Jun. 23, 2008, now abandoned.

(60) Provisional application No. 60/638,366, filed on Dec. 21, 2004, provisional application No. 60/671,796, filed on Apr. 15, 2005, provisional application No. 60/945,493, filed on Jun. 21, 2007.

(51) **Int. Cl.**

C07K 7/06	(2006.01)
C07K 14/47	(2006.01)
A01N 1/02	(2006.01)

(52) **U.S. Cl.**
CPC ***A01N 1/0226*** (2013.01)

(58) **Field of Classification Search**
CPC C07K 7/06; C07K 7/08; C07K 14/705; C07K 14/47
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,234,809	A	8/1993	Boom et al.
6,685,971	B2	2/2004	Xu et al.
6,991,813	B2	1/2006	Xu et al.
7,098,190	B1	8/2006	Becker et al.
7,888,319	B2	2/2011	Gourdie et al.
2003/0108886	A1	6/2003	Finn et al.
2003/0215424	A1	11/2003	Seul et al.
2005/0053918	A1	3/2005	Barnea et al.
2005/0075280	A1	4/2005	Larsen et al.
2008/0095819	A1	4/2008	Gourdie et al.
2009/0215665	A1	8/2009	Gourdie et al.
2011/0130345	A1	6/2011	Rohrer et al.

FOREIGN PATENT DOCUMENTS

JP	2003-238441	A	8/2003
WO	WO 00/44409		8/2000
WO	WO 00/69896		11/2000
WO	WO 02/094981		11/2000
WO	WO 02/42422		5/2002
WO	WO 03/014303		2/2003
WO	WO 03/032964		4/2003
WO	WO 2006/069181	A2	6/2006
WO	WO 2006/134494	A2	12/2006

OTHER PUBLICATIONS

Alonso L, Fuchs E. Stem cells of the skin epithelium. Proc Natl Acad Sci USA. Sep. 30, 2003; 100 Suppl 1: 11830-5, 2003.

Angst, B.D., Khan, L.U., Severs, N.J., Whitely, K., Rothely, S., Thompson, RP., Magee, A.I., and Gourdie, RG. (1997). Dissociated spatial patterning of gap junctions and cell adhesion junctions during postnatal differentiation of ventricular myocardium. Circulation Research 80, 88-94.

Barker RJ, Gourdie RG. JNK bond regulation: why do mammalian hearts invest in connexin43? Circ Res. Oct. 4, 2002;91 (7):556-8.

Barker RJ, Price RL, Gourdie RG. Increased co-localization of connexin43 and ZO-1 in dissociated adult myocytes. Cell Commun Adhes. 2001; 8(4-6):205-8.

Barker, RJ., and Gourdie, R.G. (Jan. 10, 2002). Connexin Interacting Proteins. In: Heart Cell Coupling and Impulse Propagation in Health and Disease. Eds., De Mello W.C. and Janse M.J., Kluwer, Boston, pp. 25-50.

Barker, RJ., Price, RL., and Gourdie, R.G. (2002). Increased association of ZO-1 with connexin43 during remodeling of cardiac gap junctions. Circ Res 90,317-324.

Bucci, M. et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation Nat. Med. 6,1362-1367 (2000).

Bukauskas, F.F., Jordan, K., Bukauskiene, A., Bennett, M.V., Lampe, P.O., Laird, D.W., and Verselis, V.K. (2000). Clustering of connexin 43-enhanced green fluorescent protein gap junction channels and functional coupling in living cells. Proc Natl Acad Sci USA 97, 2556-2561.

(Continued)

Primary Examiner — Karen Cochrane Carlson
(74) *Attorney, Agent, or Firm* — Cooley LLP

(57) **ABSTRACT**

The present disclosure provides compositions and methods for treating or preventing macular degeneration in a subject. The disclosure also provides compositions and methods for preserving organs and tissues for transplantation, and for preventing cellular injury in organs or in subjects.

26 Claims, 10 Drawing Sheets